iPSC– tag –
-
EUDA Health Partners with GO POSB and SIIT to Accelerate Off-the-Shelf iPSC Cell Therapy for Oncology and Wellness
Stock Titan Singapore Overview EUDA Health announced a collaboration to integrate GO POSB's iPSC platform with SIIT's NK and NK-TCR cell engineering capabilities, aiming to advance off-the-shelf cell therapy programs in oncology and well... -
Advancements in Cell and Gene Therapy Manufacturing: Automation, Cost Reduction, and Scalability Revolutionize Patient Access
Bioprocessing Summit Europe International Overview The cell and gene therapy (CGT) manufacturing sector faces significant operational challenges, including high costs and scalability constraints, particularly due to raw material variabil... -
XellSmart Secures FDA Fast Track Designation for Off-the-Shelf iPSC-Derived Cell Therapy XS411 for Parkinson’s Disease
BioSpace (XellSmart) USA Overview XellSmart announced that its allogeneic, off-the-shelf iPSC-derived cell therapy candidate, XS411, for Parkinson's disease has received Fast Track Designation (FTD) from the U.S. FDA. XS411 aims to repla... -
Fate Therapeutics’ iPSC-Derived CAR-T FT819 Shows Safety and Improved Skin Scores in Refractory Systemic Sclerosis Phase 1; Repligen Acquires BioLife Solutions for $1.5 Billion
DeciBio USA Overview July 2026 highlights in next-generation therapeutics include Fate Therapeutics' preliminary Phase 1 data for FT819, an iPSC-derived CD19-targeted CAR-T cell therapy for treatment-refractory systemic sclerosis, demons... -
NueCell Bio Launches as Translational Partner to Accelerate Cell Therapies from Discovery to GMP Manufacturing
PR Newswire USA Overview NueCell Bio has officially launched as a new "translational partner" dedicated to accelerating cell therapy products from scientific discovery through GMP-compliant manufacturing and clinical readiness. The compa... -
ClinicalTrials.gov Updates Phase 2 Trial Registration for iPSC-Derived Retinal Pigment Epithelium Cell Transplantation for Age-Related Macular Degeneration
ClinicalTrials.gov USA Overview Information regarding a Phase 2 clinical trial for iPSC-derived Retinal Pigment Epithelium (RPE) cell transplantation targeting Age-related Macular Degeneration (AMD) has been updated or newly registered o... -
Japan’s Reprocell and University Announce Joint Development of iPSC Differentiation Protocol, Enhancing Cell Therapy Product Uniformity and Scalability
Reprocell / University Announcement Japan Overview Japanese regenerative medicine company Reprocell, in collaboration with a prominent university research lab, announced the joint development of a novel protocol for high-efficiency diffe... -
FDA Bestows RMAT Status on iPSC-Derived Cell Therapy for Intractable Disease, Poised to Accelerate Clinical Development
Company Announcement / Specialized Media USA Overview A regenerative medicine firm has announced its iPSC-derived cell therapy program for an intractable disease has received Regenerative Medicine Advanced Therapy (RMAT) designation from... -
Company Announces Positive Safety and Early Efficacy Signals in Phase 1 Clinical Trial of iPSC-Derived Retinal Cell Therapy, Aims for Phase 2 This Year
Endpoints News USA Overview A cell therapy development company has reported favorable safety data and initial efficacy signals from its ongoing Phase 1 clinical trial of an iPSC-derived cell therapy for a specific ocular disease. This th... -
Stealth Cell Therapy Startup Secures Series B, Accelerating iPSC-Derived Neurodegenerative Candidate Towards IND
Specialized Media / Company Announcement USA Overview An undisclosed cell therapy startup has successfully closed its Series B funding round, securing substantial capital. This investment will accelerate preclinical development and suppo...
